Hepatitis B Trial, Recruiting (NCT04139850)

Hepatitis B Trial, Recruiting NCT04139850 Sponsor: Yonsei University Condition: Hepatitis B

Printed from Voxsanity (voxsanity.com.au) — NCT04139850 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hepatitis B

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are 20 years of age or older (above 19 years).
People who have been diagnosed with chronic hepatitis B, with a positive HBsAg test result lasting more than 6 months.
People who are already receiving regular check-ups or monitoring for chronic hepatitis B at a medical facility.
People who are able to attend follow-up visits as required by the study schedule.
People who have given written consent to participate, or whose legal guardian has given written consent on their behalf.

Who may not be able to join:

People who have been diagnosed with liver cancer (hepatocellular carcinoma, or HCC) before enrolling in the trial.
People who have had any other type of cancer (other than liver cancer) within the past 5 years.
People who also have hepatitis C or HIV.
People who have serious health conditions such as advanced liver failure, end-stage kidney disease, or severe heart failure.
People whose situation is considered not suitable for the purposes of this research for other reasons (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +82-2-2228-1936

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04139850

Sponsor: Yonsei University

Phase: Not Applicable

Status: Recruiting

Condition: Hepatitis B

Trial contact: +82-2-2228-1936

More information: https://clinicaltrials.gov/study/NCT04139850

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are 20 years of age or older (above 19 years).
People who have been diagnosed with chronic hepatitis B, with a positive HBsAg test result lasting more than 6 months.
People who are already receiving regular check-ups or monitoring for chronic hepatitis B at a medical facility.
People who are able to attend follow-up visits as required by the study schedule.
People who have given written consent to participate, or whose legal guardian has given written consent on their behalf.

Who may not be able to join:

People who have been diagnosed with liver cancer (hepatocellular carcinoma, or HCC) before enrolling in the trial.
People who have had any other type of cancer (other than liver cancer) within the past 5 years.
People who also have hepatitis C or HIV.
People who have serious health conditions such as advanced liver failure, end-stage kidney disease, or severe heart failure.
People whose situation is considered not suitable for the purposes of this research for other reasons (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Yonsei University

Registry

ClinicalTrials.gov

Start date

25 September 2015

Est. completion

1 August 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Development of liver cirrhosis, decompensation or liver cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov